Article
Immune landscape of isocitrate dehydrogenase-stratified primary and recurrent human gliomas.
Neuro-oncology - 5 Dec 2024
Gupta Pravesh, Dang Minghao, Oberai Shivangi, Migliozzi Simona, Trivedi Rakesh, Kumar Gayatri, Peshoff Mekenzie, Milam Nancy, Ahmed Aml, Bojja Krishna, Tran Tuan M, Gumin Joy, Kamiya-Matsuoka Carlos, Huse Jason, Cox Kathryn, Li Jianzhuo, Shehwana Huma, Sheth Sameer A, Saxon Rodriguez, Baohua Sun, Parker Kerrigan Brittany, Maheshwari Atul, Parra Cuentas Edwin Roger, Navin Nicholas E, Heimberger Amy B, Lang Frederick F, Iavarone Antonio, Clise-Dwyer Karen, Wang Linghua, Bhat Krishna P
Abstract excerpt
BACKGROUND: Human gliomas are classified using isocitrate dehydrogenase (IDH) status as a prognosticator; however, the influence of genetic differences and treatment effects on ensuing immunity remains unclear. METHODS: In this study, we used sequential single-cell transcriptomics on 144 678 and spectral cytometry on over 2 million immune cells encompassing 48 human gliomas to decipher their immune landscape....
Topics
Join the communities discussing this publication.
